← All trials
NCT04432376
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Sep 30, 2021
- Completion date
- Oct 31, 2021
- First posted
- Jun 16, 2020
- Last posted
- Jun 17, 2020
- Enrollment
- 390
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hill Dermaceuticals, Inc.Lead sponsor
- University of California, San DiegoOverall official - principal investigator
- University of MissouriOverall official - principal investigator
- Abond CRO Inc.Collaborator
- Advanced ENT and AllergyOverall official - principal investigator
- Carolina ENTOverall official - principal investigator
- DaVinci Research LLCOverall official - principal investigator
- DelRicht ResearchOverall official - principal investigator
- OnSite Clinical SolutionsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.